Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy
作者： Michael F. Press , Guido Sauter , Marc Buyse , Leslie Bernstein , Roberta Guzman
关键词:
摘要: Purpose Approximately 35% of HER2-amplified breast cancers have coamplification the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target anthracyclines. This study was designed to evaluate whether TOP2A alterations may predict incremental responsiveness anthracyclines in some cancers. Methods A total 4,943 were analyzed for and HER2. Primary tumor tissues from patients with metastatic cancer treated trial chemotherapy plus/minus trastuzumab studied amplification/deletion HER2 as test set followed by evaluation malignancies two separate, large trials changes these same genes validation set. Association between clinical outcomes determined. Results Test cases containing amplification doxorubicin cyclophosphamide (AC) plus trastuzumab, demonstrated longer progression-free survival compared those AC a...
sci-hub.se 参考文章(69)
M van de Vijver, R van de Bersselaar, P Devilee, C Cornelisse, J Peterse, R Nusse, Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Molecular and Cellular Biology. ,vol. 7, pp. 2019- 2023 ,(1987) , 10.1128/MCB.7.5.2019
Michael F. Press, Dennis J. Slamon, Kerry J. Flom, Jinha Park, Jian-Yuan Zhou, Leslie Bernstein, Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens Journal of Clinical Oncology. ,vol. 20, pp. 3095- 3105 ,(2002) , 10.1200/JCO.2002.09.094
M N Levine, V H Bramwell, K I Pritchard, B D Norris, L E Shepherd, H Abu-Zahra, B Findlay, D Warr, D Bowman, J Myles, A Arnold, T Vandenberg, R MacKenzie, J Robert, J Ottaway, M Burnell, C K Williams, D Tu, Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. ,vol. 16, pp. 2651- 2658 ,(1998) , 10.1200/JCO.1998.16.8.2651
E R Fisher, P Jochimsen, S Legault-Poisson, B Fisher, C Redmond, D L Wickerham, D Bowman, H Schipper, N Wolmark, R Sass, Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. Journal of Clinical Oncology. ,vol. 7, pp. 572- 582 ,(1989) , 10.1200/JCO.1989.7.5.572
Early Breast Cancer Trialists' Collaborative Group, None, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials The Lancet. ,vol. 365, pp. 1687- 1717 ,(2005) , 10.1016/S0140-6736(05)66544-0
Tero A.H. Järvinen, Edison T. Liu, Her-2/neu and Topoisomerase iiα in Breast Cancer Breast Cancer Research and Treatment. ,vol. 78, pp. 299- 311 ,(2003) , 10.1023/A:1023077507295
Mariantonietta Colozza, Angelo Sidoni, Anna Maria Mosconi, Antonio Cavaliere, Giancarlo Bisagni, Stefania Gori, Verena De Angelis, Antonio Frassoldati, Roberta Cherubini, Alberto Rosa Bian, Carmelina Rodinò, Bruno Mazzocchi, Zhasmina Mihailova, Emilio Bucciarelli, Maurizio Tonato, Italian Oncology Group for Clinical Research, HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. Clinical Breast Cancer. ,vol. 6, pp. 253- 259 ,(2005) , 10.3816/CBC.2005.N.028
Angelo Di Leo, Jorma Isola, F Piette, Bent Ejlertsen, KI Pritchard, JM Bartlett, Christine Desmedt, Denis Larsimont, M Tanner, Henning Mouridsen, Frances P O'Malley, C Twelves, Fatima Cardoso, CJ Poole, MJ Piccart, ME Buyse, None, A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Cancer Research. ,vol. 69, pp. 705- ,(2009) , 10.1158/0008-5472.SABCS-705
SF Hoare, CA Freeman, JC Coutts, JM Varley, L James, WN Keith, Identification of genetic changes associated with drug resistance by reverse in situ hybridization. British Journal of Cancer. ,vol. 75, pp. 275- 282 ,(1997) , 10.1038/BJC.1997.45
Ann D. Thor, Donald A. Berry, Daniel R. Budman, Hyman B. Muss, Timothy Kute, I. Craig Henderson, Maurice Barcos, Constance Cirrincione, Susan Edgerton, Craig Allred, Larry Norton, Edison T. Liu, erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer Journal of the National Cancer Institute. ,vol. 90, pp. 1346- 1360 ,(1998) , 10.1093/JNCI/90.18.1346